5′-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients
- 15 April 2004
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 103 (8) , 3055-3057
- https://doi.org/10.1182/blood-2003-07-2521
Abstract
White and Japanese patients require different warfarin dosages to achieve therapeutic anticoagulation, but this can be only partly explained by genetic variability in the coding region of CYP2C9—a critical enzyme in the drug's metabolism. Accordingly, analysis of the -2.1-kb 5′-flanking region of CYP2C9 was undertaken in 22 white and 38 Japanese patients whose unbound oral clearance of S-warfarin had been previously determined. Thirteen single nucleotide polymorphisms (SNPs) were identified, some of which were in linkage disequilibrium with functionally defective coding region variants. Those 5′-flanking patterns linked with at least one CYP2C9*3 allele or CYP2C9*2/*3 were associated with reduced CYP2C9 activity and warfarin dose. Japanese patients possessing the wild-type promoter and coding sequences had significantly (P < .01) greater CYP2C9 activity than white patients with the corresponding genotype. In conclusion, either unidentified polymorphisms further upstream in the promoter region or environmental factor(s) account for the differences in the warfarin doses between whites and Japanese. (Blood. 2004;103: 3055-3057)Keywords
This publication has 15 references indexed in Scilit:
- Population differences in S‐warfarin metabolism between CYP2C9 genotype‐matched Caucasian and Japanese patientsClinical Pharmacology & Therapeutics, 2003
- Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarinThe Pharmacogenomics Journal, 2003
- Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patientsBlood, 2001
- Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: In vitro and in vivo studiesClinical Pharmacology & Therapeutics, 2001
- Optimal Intensity of Warfarin Therapy for Secondary Prevention of Stroke in Patients with Nonvalvular Atrial FibrillationStroke, 2000
- Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes*Clinical Pharmacology & Therapeutics, 1998
- Transcriptional Regulation of Human CYP2C Genes: Functional Comparison of CYP2C9 and CYP2C18 Promoter RegionsBiochemistry, 1995
- Gene Structure and Upstream Regulatory Regions of Human CYP2C9 and CYP2C18Biochemical and Biophysical Research Communications, 1993
- Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactionsChemical Research in Toxicology, 1992
- Studies on the optical enantiomorphs of warfarin in manClinical Pharmacology & Therapeutics, 1974